Tyrosine News and Research

RSS

Dabrafenib shows significant anti-tumour activity in BRAF V600E mutant non-small cell lung cancer

The BRAF inhibitor dabrafenib has significant anti-tumour activity in patients with advanced BRAF V600E mutant non-small cell lung cancer whose disease has progressed after chemotherapy, according to phase II data presented at the ESMO 2014 Congress in Madrid, Spain.

29 Sep 2014

Oral afatinib significantly improves progression-free survival in patients with head and neck cancer

The tyrosine kinase inhibitor afatinib significantly improved progression-free survival compared to methotrexate in patients with recurrent or metastatic squamous cell carcinoma of the head and neck after failure of platinum-based chemotherapy, the results of a phase III trial show.

29 Sep 2014

Daiichi Sankyo, Ambit Biosciences enter into definitive merger agreement

Daiichi Sankyo Company, Ltd. (hereinafter Daiichi Sankyo) and Ambit Biosciences, jointly announced today that they have entered into a definitive merger agreement under which Daiichi Sankyo will acquire all of the outstanding common stock of Ambit Biosciences for $15 per share in cash through a tender offer followed by a merger with a subsidiary of Daiichi Sankyo, or approximately $315 million on a fully diluted basis.

29 Sep 2014

Researchers develop new strategy for reducing serious side effects of modern anticancer drugs

An interdisciplinary team of researchers from the University of Vienna (Institute of Inorganic Chemistry) and the Medical University of Vienna (Institute for Cancer Research) has successfully developed a new strategy for reducing the often serious side effects of an important class of modern anticancer drugs (tyrosine kinase inhibitors).

26 Sep 2014

NCCN ORP awards four research grants to advance development of nintedanib

The National Comprehensive Cancer Network Oncology Research Program has awarded four grants to investigators to evaluate and define the clinical effectiveness of the investigational compound nintedanib (BIBF 1120) in non-small cell lung, colorectal, and gastrointestinal cancers.

25 Sep 2014

Antacids linked to reduced erlotinib efficacy

Acid suppression therapy may negatively impact outcome among patients receiving erlotinib for advanced non-small-cell lung cancer, Canadian study findings show.

24 Sep 2014

XAGE1 antibody confers survival benefits to lung adenocarcinoma patients

Patients with advanced lung adenocarcinoma who produce the XAGE1 antibody appear to survive twice as long as those who do not produce it, Japanese study data show.

24 Sep 2014

Novel treatment makes life-saving difference to young patients with Ph-like ALL

St. Jude Children's Research Hospital investigators found that adjusting treatment based on early response to chemotherapy made a life-saving difference to young patients with an acute lymphoblastic leukemia (ALL) subtype associated with a poor outcome.

24 Sep 2014

Immature blood vessels linked to poor sunitinib response

Patients with clear-cell renal cell carcinoma with relatively mature blood vessels respond better to sunitinib and have fewer metastatic sites than those with immature vessels, a study has found.

22 Sep 2014

Ramucirumab effective second-line option for NSCLC

The monoclonal antibody ramucirumab, when added to second-line docetaxel, significantly improves the overall survival of patients with stage IV non-small-cell lung cancer, show the findings of the REVEL trial.

17 Sep 2014

Survival benefits with erlotinib plus bevacizumab in EGFR-Mutated NSCLC

Combining erlotinib with bevacizumab could prolong progression-free survival in patients being treated for epidermal growth factor receptor-mutated non-small-cell lung cancer, phase II trial results suggest.

17 Sep 2014

OGT to highlight NGS and FISH methods for tumour screening at BSGM 2014

Oxford Gene Technology, The Molecular Genetics Company, is inviting attendees of the British Society for Genetic Medicine annual conference to its seminar entitled ‘Approaches to tumour screening and therapy stratification: case studies in Non-Small Cell Lung Cancer’ on Monday 22nd September, 13.10-13.50, room 2N.

From Oxford Gene Technology 17 Sep 2014

Growth factors present in human breast milk may protect against intestinal damage

Studies Suggest that ErbB4 Receptor Activation May Be a Novel Therapeutic Avenue for Intestinal Diseases Involving Epithelial Cell Death, According to Research Published in The American Journal of Pathology

10 Sep 2014

Internal production of hydrogen peroxide can lead cells to exit cell cycle and become senescent

What happens inside cells when they detect the activation of a cancer-inducing gene? Sometimes, cells are able to signal internally to stop the cell cycle. Such cells are able to enter, at least for a time, a protective non-growth state.

30 Aug 2014

Mutant allele frequency predicts lung cancer TKI response

Tyrosine kinase inhibitor sensitivity may be predicted by the frequency of a point mutation in the epidermal growth factor receptor gene, suggests a study of Japanese patients with advanced lung adenocarcinoma.

28 Aug 2014

Researchers examine impact of BIM deletion on survival outcomes of advanced NSCLC patients

Bcl-2-like protein 11 (BIM) deletion in advanced non-small cell lung cancer (NSCLC) is associated with shorter progression free survival (PFS) in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) or chemotherapy treated Asian patients.

25 Aug 2014

Erlotinib feasible in KRAS wild-type lung adenocarcinoma

Erlotinib is a valid treatment option for patients with KRAS wild-type lung adenocarcinoma refractory to chemotherapy, study data show.

21 Aug 2014

Researchers identify mutated forms of gene that encodes unregulated enzyme driving CML

Researchers at Huntsman Cancer Institute (HCI) at the University of Utah have identified and characterized mutated forms of the gene that encodes BCR-ABL, the unregulated enzyme driving the blood cancer chronic myeloid leukemia (CML).

21 Aug 2014

EGFR biomarkers predict NSCLC response to vandetanib

Biomarker analyses of tumour samples from the ZODIAC study indicate that epidermal growth factor receptor gene copy number and mutation status may help identify the non-small-cell lung cancer patients most likely to benefit from treatment with vandetanib plus docetaxel.

20 Aug 2014

Glenmark announces discovery and initiation of IND enabling studies of innovative bispecific antibody

Glenmark Pharmaceuticals S.A. (GPSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Limited India (GPL), announces the discovery and initiation of IND enabling studies of a novel clinical development candidate, GBR 1302, a HER2xCD3 bispecific antibody.

20 Aug 2014

Tyrosine News and Research

Dabrafenib shows significant anti-tumour activity in BRAF V600E mutant non-small cell lung cancer

Oral afatinib significantly improves progression-free survival in patients with head and neck cancer

Daiichi Sankyo, Ambit Biosciences enter into definitive merger agreement

Researchers develop new strategy for reducing serious side effects of modern anticancer drugs

NCCN ORP awards four research grants to advance development of nintedanib

Antacids linked to reduced erlotinib efficacy

XAGE1 antibody confers survival benefits to lung adenocarcinoma patients

Novel treatment makes life-saving difference to young patients with Ph-like ALL

Immature blood vessels linked to poor sunitinib response

Ramucirumab effective second-line option for NSCLC

Survival benefits with erlotinib plus bevacizumab in EGFR-Mutated NSCLC

OGT to highlight NGS and FISH methods for tumour screening at BSGM 2014

Growth factors present in human breast milk may protect against intestinal damage

Internal production of hydrogen peroxide can lead cells to exit cell cycle and become senescent

Mutant allele frequency predicts lung cancer TKI response

Researchers examine impact of BIM deletion on survival outcomes of advanced NSCLC patients

Erlotinib feasible in KRAS wild-type lung adenocarcinoma

Researchers identify mutated forms of gene that encodes unregulated enzyme driving CML

EGFR biomarkers predict NSCLC response to vandetanib

Glenmark announces discovery and initiation of IND enabling studies of innovative bispecific antibody

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News